Israel Wiznitzer

Assistant Professor of Clinical

  • 1136 Citations
1985 …2017

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Israel Wiznitzer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1136 Citations
  • 5 Article
  • 1 Chapter
  • 207 Scopus citations

    AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP

    Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., Conklin, G. T., Lichtin, A. E., Lyons, R. M., Nieva, J., Wasser, J. S., Wiznitzer, I., Kelly, R., Chen, C. F. & Nichol, J. L., Oct 19 2006, In : New England Journal of Medicine. 355, 16, p. 1672-1681 10 p.

    Research output: Contribution to journalArticle

  • 401 Scopus citations

    A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

    Rader, J. S., Clarke-Pearson, D., Moore, M., Carson, L., Holloway, R., Kao, M. S., Wiznitzer, I. & Douglass, E. C., Nov 2003, In : Gynecologic oncology. 91, 2, p. 318-325 8 p.

    Research output: Contribution to journalArticle

  • 13 Scopus citations

    Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer

    Kubista, E., Glaspy, J., Holmes, F. A., Green, M. D., Hackett, J., Neumann, T., Marques, F., Meza, L., Miles, D., Moore, M., O'Shaughnessy, J., Piccart, M. J., Richardson, G. E., Samonigg, H., Santoro, A., Savin, M., Schaafsma, M. R., Siena, S., Shogan, J., Vukelja, S. & 1 others, Wiznitzer, I., Feb 2003, In : Clinical breast cancer. 3, 6, p. 391-398 8 p.

    Research output: Contribution to journalArticle

  • 48 Scopus citations

    Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

    Holmes, F. A., O'Shaughnessy, J. A., Vukelja, S., Jones, S. E., Shogan, J., Savin, M., Glaspy, J., Moore, M., Meza, L., Wiznitzer, I., Neumann, T. A., Hill, L. R. & Liang, B. C., Feb 1 2002, In : Journal of Clinical Oncology. 20, 3, p. 727-731 5 p.

    Research output: Contribution to journalArticle

  • 456 Scopus citations